Literature DB >> 12883359

Antiapoptotic action of 1alpha,25-dihydroxyvitamin D3 in primary human melanocytes.

Bettina Sauer1, Lars Ruwisch, Burkhard Kleuser.   

Abstract

1alpha,25-Dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] has been shown to induce cell growth arrest and to possess differentiation-inducing behaviour in both primary melanocytes and melanoma cell lines. Moreover, in several melanoma cell lines it has been demonstrated that the antiproliferative action is accompanied by an increase in apoptosis. In contrast, here we show that physiological concentrations of 1,25-(OH)(2)D(3) did not induce apoptosis in primary melanocytes despite a cell growth inhibitory effect. Furthermore, treatment with 1,25-(OH)(2)D(3) made melanocytes resistant to several inductors of programmed cell death, including tumour necrosis factor-alpha and ultraviolet radiation. The antiapoptotic effect of 1,25-(OH)(2)D(3) was completely abolished by the addition of N,N-dimethylsphingosine, which blocks the formation of the sphingolipid degradation product sphingosine 1-phosphate (S1P), suggesting a crucial role for this sphingolipid in 1,25-(OH)(2)D(3)-mediated cytoprotection. Indeed, stimulation of melanocytes with S1P also resulted in an antiapoptotic action. In addition, S1P induced cell growth arrest of human melanocytes. This was an unexpected finding, as S1P is generally known as a potent mitogenic molecule in a variety of cells, including fibroblasts. As both 1,25-(OH)(2)D(3) and S1P have been identified to modify the Bcl-2/Bax ratio in epithelial cells, we also measured the expressions of these proteins; however, treatment of melanocytes with either 1,25-(OH)(2)D(3) or S1P did not alter the Bcl-2/Bax ratio. In conclusion, 1,25-(OH)(2)D(3) was shown to protect human melanocytes from apoptosis by formation of S1P, which is opposite to its apoptotic action in diverse melanoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883359     DOI: 10.1097/00008390-200308000-00002

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  11 in total

Review 1.  The circadian control of skin and cutaneous photodamage.

Authors:  Joshua A Desotelle; Melissa J Wilking; Nihal Ahmad
Journal:  Photochem Photobiol       Date:  2012-02-21       Impact factor: 3.421

2.  Pilot study on the bioactivity of vitamin d in the skin after oral supplementation.

Authors:  Clara Curiel-Lewandrowski; Jean Y Tang; Janine G Einspahr; Yira Bermudez; Chiu Hsieh Hsu; Melika Rezaee; Alex H Lee; Joseph Tangrea; Howard L Parnes; David S Alberts; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-02

Review 3.  New vitamin D analogs as potential therapeutics in melanoma.

Authors:  Paulina Szyszka; Michal A Zmijewski; Andrzej T Slominski
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

Review 4.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

Review 5.  Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system.

Authors:  Mercedes Garcia-Gil; Federica Pierucci; Ambra Vestri; Elisabetta Meacci
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

Review 6.  The interplay between bioactive sphingolipids and steroid hormones.

Authors:  Natasha C Lucki; Marion B Sewer
Journal:  Steroids       Date:  2010-02-04       Impact factor: 2.668

Review 7.  Vitamin D in cutaneous carcinogenesis: part II.

Authors:  Jean Y Tang; Teresa Fu; Christopher Lau; Dennis H Oh; Daniel D Bikle; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2012-11       Impact factor: 11.527

8.  DMS triggers apoptosis associated with the inhibition of SPHK1/NF-κB activation and increase in intracellular Ca2+ concentration in human cancer cells.

Authors:  Kan Chen; Qiuwei Pan; Ying Gao; Xinyan Yang; Shibing Wang; Maikel P Peppelenbosch; Xiangdong Kong
Journal:  Int J Mol Med       Date:  2013-10-30       Impact factor: 4.101

9.  Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature.

Authors:  Kirsten C Webb; Magdalena Harasimowicz; Monica Janeczek; Jodi Speiser; James Swan; Rebecca Tung
Journal:  Case Rep Dermatol Med       Date:  2017-03-23

10.  Assessment of Serum Vitamin D Levels in Patients with Vitiligo in Jordan: A Case-Control Study.

Authors:  Diala M Alshiyab; Firas A Al-Qarqaz; Leen H Heis; Jihan M Muhaidat; Wlla S Eddin; Ausama A Atwan
Journal:  Dermatol Res Pract       Date:  2019-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.